Citi Trends

Business

Lazard Posts Record Advisory Revenue in 2025, Citing Strategic Gains and Asset Management Turnaround

Lazard Ltd. reported strong fourth-quarter and full-year 2025 results, driven by record financial advisory fees and a rebound in assets under management. Executives framed the performance as validation of the firm's long-term 'Lazard 2030' strategy, highlighting talent investments and a robust pipeline for future growth.

Jan 30, 2026

Business

Meta Stock Surges Over 10% as Analysts Boost Price Target, Citing AI Leadership

Shares of Meta Platforms soared Thursday, fueled by a significant price target upgrade from BofA Securities. The rally comes despite the company reporting a slight dip in full-year profit, as investors focus on strong revenue growth and the company's positioning in the artificial intelligence race.

Jan 30, 2026

World

Texas Man Sues California Doctor in First Private Action Under New Abortion Pill Ban

A landmark lawsuit filed in Texas federal court targets a California physician for allegedly mailing abortion medication across state lines, testing a new state law that empowers private citizens to act as enforcers and setting up a clash with California's protective 'shield law'.

Feb 2, 2026

Business

Disney Stock Tumbles After Q1 Earnings Miss: Is the Sell-Off an Overreaction?

Walt Disney Co. shares fell sharply following a quarterly earnings report that showed a decline in profit, breaking key technical support levels. While some investors fled, Citigroup analysts see the drop as a buying opportunity for the long term.

Feb 2, 2026

US

Judge Lifts Restraining Order, Allows DHS to Proceed with Evidence Disposal in ICE Shooting Case

A federal judge in Minnesota has rescinded an order that prevented the Department of Homeland Security from destroying evidence connected to the fatal shooting of U.S. citizen Alex Pretti by ICE agents, allowing the controversial disposal process to move forward.

Feb 2, 2026

Business

Relay Therapeutics Gains Analyst Backing as Pipeline Shows Promise in Competitive Cancer Drug Landscape

Oppenheimer upgrades Relay Therapeutics (RLAY) to Outperform, citing the strength of its mutant-selective inhibitor pipeline and upcoming catalysts in the breast cancer treatment arena.

Feb 2, 2026

Business

Jim Cramer Backs Carrier Global, Advising Investors to 'Buy and Hold'

CNBC's Jim Cramer endorsed Carrier Global Corp. (NYSE:CARR) on his recent show, praising CEO Dave Gitlin's leadership and strategic acquisition. He recommended investors buy the stock for the long term, citing confidence in the company's positioning within the climate solutions sector.

Feb 2, 2026

Business

Visa Shares Climb on Strong Quarterly Results, Fueled by Consumer Spending and Digital Innovation

The payments giant reported a 15% jump in revenue, beating Wall Street estimates, as it positions itself to capitalize on emerging trends in stablecoins and AI-driven commerce.

Feb 2, 2026

Business

Silver's Meteoric Rise: Analysts See Path to $150 as New Era Dawns

Silver's explosive surge past $100 has reshaped the commodity landscape. With Citi and prominent strategists forecasting a run toward $150, the metal is now seen as a volatile barometer of macro fears, structural deficits, and relentless industrial demand, establishing a potential new floor above $65.

Feb 2, 2026

Business

Brookdale Senior Living Shares Surge as RBC Capital Backs Bullish Outlook

Shares of Brookdale Senior Living (BKD) climbed over 7% after RBC Capital reaffirmed its confidence in the company's long-term prospects, citing strong industry tailwinds and improved operational positioning.

Feb 2, 2026

Business

Sweet Century Ends in Chapter 11: Primrose Candy Co., a 96-Year-Old Icon, Seeks Bankruptcy Protection

Primrose Candy Co., an Illinois-based confectioner with roots stretching back to the Great Depression, has filed for Chapter 11 bankruptcy, citing mounting debts, rising costs, and shifting consumer tastes that have eroded its once-stable business.

Feb 2, 2026

Business

FDA Delays Aquestive's Anaphylm Epinephrine Film, Demands Human Factors Revisions

The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.

Feb 2, 2026

World

Government Shutdown Forces Delay of Key January Jobs Report

The Bureau of Labor Statistics announced Monday that the highly anticipated January employment data will not be released as scheduled this Friday, citing disruptions from a partial federal government shutdown. The report will be published only after funding is restored.

Feb 2, 2026

Business

Disney Braces for Impact as International Tourism to U.S. Parks Slows

The entertainment giant signals a downturn in overseas visitors to its American resorts, with industry analysts citing geopolitical tensions and shifting travel policies as contributing factors.

Feb 2, 2026

World

China Executes Four Leaders of Myanmar-Based Crime Syndicate Over Vast Scam Empire

Chinese courts have executed four senior members of a Myanmar-based criminal organization for murder, trafficking, and running a multi-billion dollar scam operation that exploited thousands, including Chinese citizens. The move is part of a broader crackdown on cross-border cyber fraud hubs.

Feb 2, 2026

Business

Conagra Bets Big on Protein with New MEGA Breakfast Bowls, But Can It Revive Investor Appetite?

Conagra Brands launches its protein-packed Banquet MEGA Breakfast Bowls, a direct challenge to rivals in the frozen aisle. While the move aligns with consumer trends, analysts question if it's enough to offset broader financial pressures facing the packaged food giant.

Feb 2, 2026

Business

Sweetgreen Sees Price Target Boost Amid Broader Restaurant Sector Optimism

Goldman Sachs raises Sweetgreen's price target to $5.60, citing policy tailwinds for consumer spending, even as it maintains a Sell rating. The salad chain's expansion and strong revenue growth continue to draw investor attention.

Feb 2, 2026

Business

JPMorgan Boosts Celsius Target on PepsiCo Deal Momentum, Sees Alani Nu as Growth Engine

JPMorgan raises its price target for Celsius Holdings (CELH) to $77, citing upside potential from its deepening PepsiCo partnership and the expanding distribution of its Alani Nu brand ahead of Q4 earnings.

Feb 2, 2026

Business

Aptiv Gains Analyst Favor as Strategic Shift Yields 'More Realistic' Growth Outlook

Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.

Feb 2, 2026

Business

Korro Bio's KRRO-121 Emerges as Independent Value Driver, Sparking Analyst Upgrades

H.C. Wainwright and Chardan Capital upgrade Korro Bio (KRRO) to Buy, citing the independent potential of its RNA-editing asset KRRO-121 and strong preclinical data as key catalysts.

Feb 2, 2026